Human vascular smooth muscle cell-monocyte interactions and metalloproteinase secretion in culture

E Lee1, A J Grodzinsky, P Libby

  • 1Harvard-MIT Division of Health Sciences and Technology, Cambridge, Mass, USA.

Insights

Monocytes stimulate vascular smooth muscle cells (SMCs) to secrete matrix metalloproteinases (MMPs) like MMP-1 and MMP-3, potentially destabilizing atherosclerotic plaques. This interaction is dependent on interleukin-1 (IL-1).

Area of Science:

  • Cardiovascular Biology
  • Atherosclerosis Research
  • Cellular Interactions

Background:

  • Atherosclerotic plaque extracellular matrix degradation can lead to lesion rupture.
  • Macrophages and vascular smooth muscle cells (SMCs) produce matrix metalloproteinases (MMPs) that degrade vascular matrix.
  • Understanding SMC-MMP regulation is crucial for plaque stability.

Purpose of the Study:

  • To investigate the interactions between human vascular SMCs and human monocytes.
  • To determine the role of these interactions in the secretion of interstitial collagenase (MMP-1) and stromelysin (MMP-3).
  • To elucidate the specific molecular mechanisms driving MMP secretion.

Main Methods:

  • Co-culture of human vascular SMCs and human monocytes.
  • Treatment of SMCs with monocyte-conditioned media.
  • Western blot analysis for MMP-1, MMP-3, and MMP-2.
  • Use of recombinant interleukin-1 receptor antagonist and anti-tumor necrosis factor-alpha antibody.

Main Results:

  • SMCs significantly increased secretion of MMP-1 and MMP-3 (over 20-fold) when co-cultured with monocytes or treated with monocyte-conditioned media.
  • Monocyte-conditioned media did not induce secretion of 72-kD gelatinase (MMP-2).
  • Interleukin-1 receptor antagonist markedly inhibited MMP-1 and MMP-3 induction, while anti-tumor necrosis factor-alpha had no significant effect.

Conclusions:

  • Monocytes induce MMP-1 and MMP-3 secretion by vascular SMCs via an IL-1-dependent pathway.
  • This monocyte-induced SMC response may contribute to atherosclerotic plaque destabilization.
  • Targeting IL-1 signaling could be a therapeutic strategy for managing plaque instability.

Related Concept Videos